Home> Products> less glucagon

{ "products": [ { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c4c88ecffe165c354dc1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction to VILDIABATE PIO\nVILDIABATE PIO is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains two active ingredients: Vildagliptin 50mg and Pioglitazone Hydrochloride 15mg. This dual-action formula targets different aspects of glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nPioglitazone Hydrochloride 15mg\nPioglitazone is a thiazolidinedione that improves insulin sensitivity in muscle and adipose (fat) tissues. It works by:\n\nIncreasing Insulin Sensitivity: Pioglitazone enhances the body's response to insulin, allowing for better glucose uptake and utilization by cells.\nReducing Hepatic Glucose Production: Pioglitazone decreases the amount of glucose produced by the liver, helping to lower fasting blood sugar levels.\nBenefits of VILDIABATE PIO\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Vildagliptin and Pioglitazone effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Vildagliptin enhances insulin secretion in response to meals, while Pioglitazone improves insulin sensitivity in peripheral tissues.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nCardioprotective Effects: Pioglitazone may provide additional cardiovascular benefits, such as improving lipid profiles and reducing inflammation, which can be beneficial for patients with diabetes who are at risk of cardiovascular diseases.\nWeight Management: While Pioglitazone may cause some weight gain due to fluid retention, Vildagliptin is generally weight neutral, balancing the overall effect on body weight.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage of VILDIABATE PIO is one tablet taken once daily, preferably with a meal to enhance absorption and reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE PIO regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-pio-134257\n", "price": 295.0, "discountamount": 88.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "meals", "EMAIL", "cells", "liver", "water", "glass", "GLP-1", "amount", "muscle", "adults", "Fasting", "adipose", "patients", "Low Risk", "exercise", "readings", "response", "Enhancing", "same time", "one tablet", "Mechanisms", "Increasing", "Guidelines", "absorption", "utilization", "Optimal Use", "information", "body weight", "Adjustments", "weight gain", "DPP-4 enzyme", "inflammation", "Introduction", "Vildagliptin", "Hypoglycemia", "sterispharma", "best results", "fat) tissues", "sterisonline", "CALL/WHATSAPP", "Administration", "VILDIABATE PIO", "glucose uptake", "Key Components", "Consistent Use", "treatment plan", "overall effect", "lipid profiles", "typical dosage", "Incretin Levels", "low blood sugar", "fluid retention", "glycemic control", "glucagon release", "DPP-4) inhibitor", "Weight Management", "insulin secretion", "incretin hormones", "different aspects", "thiazolidinedione", "peripheral tissues", "glucose regulation", "Regular monitoring", "healthcare provider", "dual-action formula", "insulin sensitivity", "blood glucose levels", "effective management", "dipeptidyl peptidase-4", "two active ingredients", "combination medication", "cardiovascular diseases", "Cardioprotective Effects", "type 2 diabetes mellitus", "meal) blood sugar levels", "glucose-dependent manner", "Recommended Dosage Dosage", "Pioglitazone Hydrochloride", "Additional Health Benefits", "Hepatic Glucose Production", "gastrointestinal side effects", "Postprandial Glucose Management", "comprehensive blood sugar control", "additional cardiovascular benefits", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1512, "imageuri": "https://productimages.withfloats.com/actual/667d3d8c5443982e2f655655.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3d8c5443982e2f655655.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:28:56.298Z", "updatedon": "2024-06-27T10:23:02.274Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-pio-/1512", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE PIO ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin hydrochloride tablets uses", "vildagliptin + metformin + glimepiride combination", "vildagliptin 50 mg side effects", "vildagliptin and pioglitazone hydrochloride" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b5587de2b5203089e01d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 850 ", "description": "VILDIABATE M 850 \nMetformin (850mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 850\nVILDIABATE M 850 is a combination medication designed to manage type 2 diabetes mellitus effectively. It combines Metformin Hydrochloride Sustained Release (SR) 850mg and Vildagliptin 50mg. This dual-action formulation targets different pathways involved in glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 850mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 850\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 850 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-850-133455", "price": 299.0, "discountamount": 89.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "treatment plan", "glucose uptake", "steady release", "typical dosage", "Key Components", "Administration", "Weight Neutral", "Consistent Use", "low blood sugar", "Incretin Levels", "gradual release", "glycemic control", "VILDIABATE M 850", "glucagon release", "Prolonged Effect", "DPP-4) inhibitor", "incretin hormones", "insulin secretion", "glucose regulation", "several mechanisms", "different pathways", "Regular monitoring", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "Intestinal Absorption", "combination medication", "dipeptidyl peptidase-4", "gastrointestinal tract", "dual-action formulation", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1504, "imageuri": "https://productimages.withfloats.com/actual/667d44a2576e8da931df856b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d44a2576e8da931df856b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:23:04.367Z", "updatedon": "2024-06-27T10:53:21.595Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-850-/1504", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 850 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/850 price", "vildagliptin and metformin hydrochloride tablets s" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b1e6870e7b20c49e6522", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 500 ", "description": "VILDIABATE M 500 \nMetformin (500mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 500\nVILDIABATE M 500 is a combination medication designed to manage type 2 diabetes mellitus effectively. It contains Metformin Hydrochloride Sustained Release (SR) 500mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 500\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 500 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-500-133454", "price": 289.0, "discountamount": 86.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "glucose uptake", "steady release", "typical dosage", "Key Components", "treatment plan", "Weight Neutral", "Consistent Use", "Administration", "Incretin Levels", "gradual release", "low blood sugar", "glycemic control", "DPP-4) inhibitor", "VILDIABATE M 500", "glucagon release", "Prolonged Effect", "incretin hormones", "insulin secretion", "several mechanisms", "different pathways", "Regular monitoring", "glucose regulation", "dual-action formula", "Insulin Sensitivity", "healthcare provider", "blood glucose levels", "Intestinal Absorption", "combination medication", "gastrointestinal tract", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1499, "imageuri": "https://productimages.withfloats.com/actual/667d4af8b567218985111efd.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d4af8b567218985111efd.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:08:22.623Z", "updatedon": "2024-06-27T11:20:23.412Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-m-500-/1499", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 500 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/1000", "vildagliptin metformin 50/500 price", "ildagliptin and metformin hydrochloride tablets si" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662af26db100e1fdc2dcc17", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 1000 ", "description": "VILDIABATE M 1000 \nMetformin (1000mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 1000\nVILDIABATE M 1000 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains Metformin Hydrochloride Sustained Release (SR) 1000mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 1000mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 1000\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin, in particular, has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 1000 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-1000-133453", "price": 319.0, "discountamount": 95.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "GLP-1", "Order", "EMAIL", "water", "glass", "liver", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "response", "readings", "same time", "Enhancing", "biguanide", "one tablet", "Guidelines", "Optimal Use", "information", "utilization", "weight gain", "Adjustments", "Introduction", "Vildagliptin", "Metformin SR", "VILDIABATE M", "sterispharma", "best results", "Hypoglycemia", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "Weight Neutral", "Consistent Use", "Administration", "treatment plan", "steady release", "typical dosage", "Key Components", "glucose uptake", "low blood sugar", "Incretin Levels", "gradual release", "SR) formulation", "glucagon release", "glycemic control", "Prolonged Effect", "DPP-4) inhibitor", "insulin secretion", "incretin hormones", "several mechanisms", "different pathways", "glucose regulation", "Regular monitoring", "dual-action formula", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "effective management", "Intestinal Absorption", "gastrointestinal tract", "combination medication", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1496, "imageuri": "https://productimages.withfloats.com/actual/6662af29d878d473a9fda03d.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662af29d878d473a9fda03d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:56:38.67Z", "updatedon": "2024-06-28T11:39:06.99Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-m-1000-/1496", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 1000 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE M 1000", "Metformin (1000mg)SR", "Vildagliptin (50mg)", "Vildagliptin 50mg side effects", "Vildagliptin tablets 50 mg uses", "Vildagliptin 50 mg price", "Vildagliptin 50 mg and metformin 500 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661adf866170d1ff8cb45d2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PM 500 ", "description": "TENELIGOLD PM 500 \nTeneligliptin 20mg, Pioglitazone 15mg & Extended Release Metformin Hydrochloride 500mg\nTENELIGOLD PM 500 is a combination medication containing Teneligliptin, Pioglitazone, and Extended-Release Metformin Hydrochloride. It is primarily prescribed for the management of type 2 diabetes mellitus, a metabolic disorder characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nTeneligliptin (20mg): Teneligliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It works by inhibiting the DPP-4 enzyme, which enhances the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones stimulate insulin secretion and inhibit glucagon release, leading to improved glucose control after meals.\n\nPioglitazone (15mg): Pioglitazone is a thiazolidinedione medication that improves insulin sensitivity in muscle and adipose (fat) tissues. It reduces glucose production in the liver and enhances glucose uptake in peripheral tissues. This action helps lower blood sugar levels and improves overall glycemic control.\n\nExtended-Release Metformin Hydrochloride (500mg): Metformin is a biguanide medication that reduces glucose production in the liver, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. Extended-release formulations provide a sustained release of the drug, allowing for once-daily dosing and potentially reducing gastrointestinal side effects.\n\nKey Benefits of TENELIGOLD PM 500:\nComprehensive Glycemic Control: The combination of Teneligliptin, Pioglitazone, and Extended-Release Metformin offers comprehensive control over fasting and postprandial (after-meal) blood sugar levels.\n\nImproved Insulin Sensitivity: Pioglitazone and Metformin work synergistically to improve insulin sensitivity in cells, leading to better utilization of glucose and reduced insulin resistance.\n\nIncretin Hormone Enhancement: Teneligliptin enhances the action of incretin hormones, which regulate insulin secretion and glucagon levels, resulting in improved glucose regulation after meals.\n\nReduced Side Effects: Extended-release formulations of Metformin may reduce gastrointestinal side effects compared to immediate-release formulations.\n\nDosage and Administration:\nThe typical dosage of TENELIGOLD PM 500 is one tablet taken orally once daily, preferably with meals.\nSwallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nFollow your doctor's instructions regarding dosage adjustments based on your medical condition and response to treatment.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-pm-500-134300", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "meals", "500mg", "EMAIL", "cells", "drugs", "GLP-1", "liver", "glass", "water", "dosing", "muscle", "action", "doctor", "fasting", "response", "treatment", "management", "one tablet", "utilization", "information", "postprandial", "Pioglitazone", "Key Benefits", "fat) tissues", "sterisonline", "sterispharma", "instructions", "DPP-4 enzyme", "CALL/WHATSAPP", "TENELIGOLD PM", "Teneligliptin", "glucose uptake", "Administration", "typical dosage", "glucose control", "glucagon levels", "glucagon release", "incretin hormones", "insulin secretion", "sustained release", "medical condition", "dosage adjustments", "metabolic disorder", "glucose regulation", "peripheral tissues", "insulin resistance", "glucose production", "healthcare provider", "insulin sensitivity", "biguanide medication", "Reduced Side Effects", "comprehensive control", "combination medication", "DPP-4) inhibitor class", "dipeptidyl peptidase-4", "high blood sugar levels", "overall glycemic control", "type 2 diabetes mellitus", "meal) blood sugar levels", "Incretin Hormone Enhancement", "thiazolidinedione medication", "Extended-release formulations", "inadequate insulin production", "intestinal glucose absorption", "gastrointestinal side effects", "Comprehensive Glycemic Control", "immediate-release formulations", "Extended-Release Metformin Hydrochloride", "glucose-dependent insulinotropic peptide", "Extended Release Metformin Hydrochloride" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1481, "imageuri": "https://productimages.withfloats.com/actual/6661adfd637f8700d7ca4512.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661adfd637f8700d7ca4512.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:39:20.713Z", "updatedon": "2024-06-28T12:21:18.417Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pm-500-/1481", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PM 500 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD PM 500", "Teneligliptin 20mg", "Pioglitazone 15mg", "Metformin Hydrochloride 500mg", "Teneligliptin Tablets 20 mg uses", "Teneligliptin 20 mg + Metformin 500", "Teneligliptin 20 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661ad3166170d1ff8cb4574", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nTENELIGOLD PIO 20/15 is a combination medication that contains Teneligliptin and Pioglitazone. It is primarily used in the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nTeneligliptin: Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the DPP-4 enzyme, which in turn enhances the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones stimulate insulin secretion and inhibit glucagon release, leading to improved glucose control after meals.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of medications. It works by improving insulin sensitivity in muscle and adipose (fat) tissues, reducing glucose production in the liver, and enhancing glucose uptake in peripheral tissues. This helps lower blood sugar levels and improves overall glycemic control.\n\nBenefits of TENELIGOLD PIO 20/15:\nComprehensive Glycemic Control: The combination of Teneligliptin and Pioglitazone addresses different aspects of glucose metabolism, providing comprehensive control over fasting and postprandial (after-meal) blood sugar levels.\n\nEnhanced Insulin Sensitivity: Pioglitazone improves insulin sensitivity in cells, allowing better utilization of glucose and reducing insulin resistance.\n\nIncretin Hormone Enhancement: Teneligliptin enhances the action of incretin hormones, which regulate insulin secretion and glucagon levels, leading to better glucose regulation after meals.\n\nCardioprotective Effects: Pioglitazone has been associated with cardiovascular benefits such as improved lipid profiles and reduced risk of cardiovascular events in some patients.\n\nHow to Use TENELIGOLD PIO 20/15:\nDosage: The typical dosage is one tablet taken orally once daily, usually with meals. Your healthcare provider will determine the appropriate dosage based on your medical condition and response to treatment.\n\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your doctor.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-pio-20-15-134077", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "risk", "turn", "Order", "EMAIL", "GLP-1", "water", "glass", "meals", "cells", "liver", "action", "muscle", "doctor", "adipose", "fasting", "patients", "response", "treatment", "one tablet", "management", "information", "medications", "utilization", "Pioglitazone", "postprandial", "fat) tissues", "DPP-4 enzyme", "sterispharma", "sterisonline", "CALL/WHATSAPP", "Teneligliptin", "teneligold-pio", "glucose uptake", "lipid profiles", "typical dosage", "Administration", "TENELIGOLD PIO", "glucagon levels", "glucose control", "glucagon release", "DPP-4) inhibitor", "incretin hormones", "medical condition", "different aspects", "insulin secretion", "glucose production", "insulin resistance", "appropriate dosage", "glucose metabolism", "glucose regulation", "peripheral tissues", "healthcare provider", "cardiovascular events", "comprehensive control", "combination medication", "dipeptidyl peptidase-4", "thiazolidinedione class", "cardiovascular benefits", "high blood sugar levels", "Cardioprotective Effects", "overall glycemic control", "type 2 diabetes mellitus", "meal) blood sugar levels", "Enhanced Insulin Sensitivity", "Incretin Hormone Enhancement", "inadequate insulin production", "Comprehensive Glycemic Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1480, "imageuri": "https://productimages.withfloats.com/actual/6661ad34c749b7962dbc4345.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661ad34c749b7962dbc4345.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:36:01.592Z", "updatedon": "2024-06-28T12:39:29.014Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1480", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD PIO 20/15", "Teneligliptin", "Pioglitazone", "Teneligliptin uses", "Teneligliptin side effects", "Teneligliptin 20mg", "Teneligliptin+Metformin", "Teneligliptin 20 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661ac5887f0960e14a2c914", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD M 500 ", "description": "TENELIGOLD M 500 \nMetformin SR (500mg), Teneligliptin (20mg)\nTENELIGOLD M 500 is a combination medication containing Metformin Hydrochloride Sustained Release (SR) 500mg and Teneligliptin 20mg. It is primarily prescribed for the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nMetformin SR 500mg is a widely used oral antidiabetic medication that belongs to the biguanide class. It works by reducing the amount of glucose produced by the liver, increasing insulin sensitivity in muscle cells, and improving glucose uptake by tissues. This helps lower blood sugar levels and improves glycemic control.\n\nTeneligliptin 20mg is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It enhances insulin secretion from pancreatic beta cells and inhibits glucagon secretion, leading to reduced blood glucose levels after meals. By targeting different pathways in glucose metabolism, Teneligliptin complements the action of Metformin, resulting in better overall glycemic control.\n\nBenefits of TENELIGOLD M 500:\nComprehensive Glycemic Control: The combination of Metformin and Teneligliptin addresses both fasting and postprandial (after-meal) blood sugar levels, providing comprehensive glycemic control throughout the day.\n\nImproved Insulin Sensitivity: Metformin improves insulin sensitivity in cells, allowing better utilization of glucose and reducing insulin resistance.\n\nEnhanced Incretin Effect: Teneligliptin enhances the incretin effect, which regulates insulin secretion and glucagon levels, leading to better glucose regulation.\n\nWeight Management: Metformin is associated with weight neutrality or modest weight loss, making it beneficial for overweight or obese individuals with diabetes.\n\nLow Risk of Hypoglycemia: The risk of hypoglycemia (low blood sugar) with TENELIGOLD M 500 is low when used appropriately, making it a safer option for many patients.\n\nHow to Use TENELIGOLD M 500:\nDosage: The typical dosage is one tablet taken orally once or twice daily, as directed by your healthcare provider. Dosage adjustments may be made based on blood sugar levels and individual response.\n\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance absorption. Swallow it whole with a glass of water, and do not crush or chew the tablet unless advised otherwise.\n\nSafety Considerations:\nMedical History: Inform your doctor about any medical conditions you have, especially kidney or liver problems, as well as any medications or supplements you are taking.\n\nPregnancy and Nursing: Discuss the risks and benefits of TENELIGOLD M 500 if you are pregnant, planning pregnancy, or breastfeeding.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-m-500-133449", "price": 122.75, "discountamount": 36.83, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "Order", "meals", "glass", "risks", "water", "EMAIL", "action", "option", "amount", "kidney", "doctor", "fasting", "reduced", "tissues", "Nursing", "Low Risk", "Benefits", "Pregnancy", "absorption", "overweight", "one tablet", "medications", "supplements", "utilization", "information", "TENELIGOLD M", "Hypoglycemia", "muscle cells", "sterispharma", "postprandial", "sterisonline", "many patients", "breastfeeding", "CALL/WHATSAPP", "typical dosage", "Administration", "liver problems", "glucose uptake", "low blood sugar", "Medical History", "glucagon levels", "biguanide class", "DPP-4) inhibitor", "Weight Management", "weight neutrality", "obese individuals", "insulin secretion", "glucose regulation", "modest weight loss", "Metformin SR 500mg", "glucose metabolism", "insulin resistance", "glucagon secretion", "different pathways", "Teneligliptin 20mg", "Dosage adjustments", "medical conditions", "insulin sensitivity", "healthcare provider", "individual response", "blood glucose levels", "Safety Considerations", "pancreatic beta cells", "combination medication", "dipeptidyl peptidase-4", "high blood sugar levels", "overall glycemic control", "Enhanced Incretin Effect", "meal) blood sugar levels", "type 2 diabetes mellitus", "oral antidiabetic medication", "gastrointestinal side effects", "inadequate insulin production", "Comprehensive Glycemic Control", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1479, "imageuri": "https://productimages.withfloats.com/actual/6661ac5c4b296a211c2d34ee.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661ac5c4b296a211c2d34ee.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:32:24.912Z", "updatedon": "2024-06-29T05:26:50.914Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-m-500-/1479", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD M 500 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD M 500", "Metformin SR (500mg)", "Teneligliptin (20mg)", "Teneligliptin Tablets 20 mg uses", "Teneligliptin 20 mg price", "Teneligliptin 20 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665efdbd66170d1ff8cb13bf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA 3D 10/100/500 SR ", "description": "GLIDAPA 3D 10/100/500 SR \nDapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg\nIntroduction\nGLIDAPA 3D 10/100/500 SR is a sophisticated, multi-mechanism oral medication designed for the management of Type 2 diabetes. It combines Dapagliflozin (10 mg), Sitagliptin (100 mg), and Metformin (500 mg, sustained release), offering a robust, integrated approach to controlling high blood glucose levels.\n\nMechanism of Action\n\nDapagliflozin (10 mg): As an SGLT2 inhibitor, Dapagliflozin promotes the excretion of glucose through urine by blocking its reabsorption in the kidneys. This helps to lower blood sugar levels and also has benefits for weight loss and cardiovascular health.\nSitagliptin (100 mg): A DPP-4 inhibitor, Sitagliptin works by enhancing the body's own ability to lower blood glucose levels in response to meals. It does this by increasing the levels of incretin hormones, which affect the pancreas to produce more insulin and less glucagon.\nMetformin SR (500 mg): Metformin works primarily by reducing glucose production in the liver, improving insulin sensitivity, and lowering glucose absorption in the gut. The sustained-release (SR) formulation ensures a steady release over time, minimizing gastrointestinal side effects and maintaining more consistent blood sugar control.\nBenefits\nGLIDAPA 3D 10/100/500 SR provides a comprehensive treatment solution by addressing several key pathways in glucose metabolism, thereby reducing the risk of both hyperglycemia and associated complications. The combination of these three active substances in a single formulation enhances convenience and potentially improves adherence to treatment protocols.\n\nDosage and Administration\n\nDosage: The recommended starting dose depends on the patient’s current treatment regimen and their specific health profile. Adjustments should be made based on effectiveness and tolerability, under the guidance of a healthcare professional.\nAdministration: This medication should be taken once daily in the morning, with or without food. The tablet should be swallowed whole to maintain the sustained release of Metformin.\nSide Effects\nPossible side effects of GLIDAPA 3D 10/100/500 SR include urinary tract and genital infections (due to Dapagliflozin), nausea or a sore throat (from Sitagliptin), and digestive issues such as diarrhea or abdominal pain (common with Metformin). Most side effects are manageable and tend to decrease over time.\n\nConclusion\nGLIDAPA 3D 10/100/500 SR is a versatile and effective option for those managing Type 2 diabetes, offering triple-action treatment in one convenient medication. It targets various aspects of diabetes management, improves glycemic control, and enhances overall quality of life. Patients are advised to maintain regular follow-ups with their healthcare provider to optimize treatment outcomes and manage any side effects.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/glidapa-3d-10-100-500-sr-134215", "price": 575.0, "discountamount": 172.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "gut", "time", "life", "risk", "food", "body", "urine", "liver", "EMAIL", "Order", "meals", "500 mg", "nausea", "tablet", "patient", "ability", "kidneys", "morning", "response", "diarrhea", "pancreas", "guidance", "benefits", "adherence", "versatile", "excretion", "Conclusion", "sore throat", "Sitagliptin", "weight loss", "Adjustments", "combination", "information", "convenience", "Introduction", "sterispharma", "Metformin SR", "reabsorption", "sterisonline", "urinary tract", "CALL/WHATSAPP", "hyperglycemia", "Dapagliflozin", "less glucagon", "effectiveness", "starting dose", "abdominal pain", "steady release", "overall quality", "SGLT2 inhibitor", "various aspects", "Type 2 diabetes", "DPP-4 inhibitor", "Dapaflozin 10 mg", "effective option", "digestive issues", "glycemic control", "Most side effects", "sustained release", "incretin hormones", "regular follow-ups", "genital infections", "blood sugar levels", "glucose metabolism", "glucose absorption", "glucose production", "treatment outcomes", "single formulation", "diabetes management", "insulin sensitivity", "healthcare provider", "treatment protocols", "several key pathways", "Administration Dosage", "Possible side effects", "cardiovascular health", "triple-action treatment", "specific health profile", "three active substances", "healthcare professional", "associated complications", "GLIDAPA 3D 10/100/500 SR", "current treatment regimen", "one convenient medication", "high blood glucose levels", "robust, integrated approach", "gastrointestinal side effects", "consistent blood sugar control", "comprehensive treatment solution", "sustained-release (SR) formulation", "sophisticated, multi-mechanism oral medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1300, "imageuri": "https://productimages.withfloats.com/actual/665efdc0e874b19df8b5f4ce.png", "tileimageuri": "https://productimages.withfloats.com/tile/665efdc0e874b19df8b5f4ce.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:42:53.803Z", "updatedon": "2024-06-04T11:42:53.803Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-3d-10-100-500-sr-/1300", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIDAPA 3D 10/100/500 SR ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }